Heterozygous point mutations or deletions of the NKX2-1 gene cause benign hereditary chorea (BHC) or a various combinations of primary hypothyroidism, respiratory distress and neurological disorders. Deletions proximal to, but not encompassing, NKX2-1 have been described in few subjects with brain-lung-thyroid syndrome. We report on a three-generation Italian family, with 6 subjects presenting BHC and harboring a genomic deletion adjacent to NKX2-1 and including the gene MBIP, recently proposed to be relevant for the pathogenesis of brain-lung-thyroid syndrome.
Here we describe a three-generation Italian family, with 6 subjects presenting with BHC and harboring a genomic deletion adjacent to NKX2-1 and including the gene MBIP, recently proposed to be relevant for the pathogenesis of brain-lung-thyroid syndrome [Kharbanda et al. 2017 ].
Patients' Data
The probands were two siblings (III-1 and III-2, pedigree in Figure 1 ) with a very similar clinical picture (Table 1) consisting of hypotonia and motor delay, a hyperkinetic movement disorder noted since infancy and recurrent pulmonary infections. They both presented dysmorphic features Thyroid function was measured in all cases during the follow-up and always resulted normal. The movement disorder spontaneously improved over time in all cases, causing little or no functional disability.
Methods
Informed consent for the genetic diagnosis was obtained from patients or parents according to the local regulations, DNA was extracted from venous peripheral blood lymphocytes according to standard procedures and was used as a template to amplify the 3 exons of the NKX2-1 gene. PCR
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fragments were analyzed by automated nucleotide sequencing using the Big-Dye terminator Ready
Reaction Kit version 2 on a 3100 Genetic Analyzer Automated Sequencer (Applied Biosystems).
Haplotype analysis was performed by SNPs array (ILLUMINA HumanCytoSNP-12 BeadChip).
For whole exome sequencing (WES), genomic DNA was processed for library enrichment according to the SeqCap EZ Exome v3.0 kit (Roche). Sequencing was performed on an Illumina®
Genome Analyzer HiSeq2500. The sequencing reads were aligned to the National Center for Biotechnology Information human reference genome (GRCh37/hg19) using the Burrows-Wheeler
Aligner (BWA). Variant calling was performed using Genome Analysis Toolkit (GATK) and
VariantStudio Data Analysis Software (Illumina®) was used for variants annotation and filtering.
Coverage analysis was performed on WES data of individuals I-1 and III-2 using CANOES (http://www.columbia.edu/~ys2411/canoes). CANOES is a bioinformatics tool based on an algorithm for the detection of rare copy number variants from exome sequencing data; it uses a regression-based approach on selected reference samples in a given dataset to estimates variance of the read counts for an affected sample.
For gene content analysis, real-time quantitative PCR (RT-qPCR) was performed using SYBR Green chemistry and primers specific to MBIP exon 1 and 8, with a single copy gene (RNaseP)
taken as a nuclear gene reference. For the analysis of transcripts, total RNA was extracted from fibroblasts patient, according to the manufacturer's instructions (RNeasy Mini Kit Qiagen). RTqPCR assay on cDNA (Go Taq R 2 step RTqPCR System) was performed using three different primers specific for amplification of NKX2-1 and and one house-keeping gene (ACTB).
Results
Because of the clinical presentation, we sequenced NKX2-1 in the proband III-1 but no mutation was found. In order to identify the genetic defect, we performed SNP-array analysis and WES.
SNP-array analysis on available DNAs from the family revealed a genomic deletion on 
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deep analysis of WES coverage data further confirmed this finding, highlighting that only MBIP has a halved copy number whereas the surrounding genes, including NKX2-1, were not affected (Supplementary Figure S1) . In order to evaluate any possible effect of the MBIP deletion on NKX2-1 expression, we measured NKX2-1 transcript levels in patients II-3, III-1 and III-2. Despite the low expression of NKX2-1 in fibroblasts, we observed a clear reduction of NKX2-1 transcript levels in our patients compared to controls, although slightly lower than the decrease observed in fibroblasts from two patients harboring mutations in NKX2-1 (Supplementary Figure S2) .
Discussion
The deletion we identified comprises a single gene, MBIP, not associated with any human disease. B. Map of the Chr.14 genomic region surrounding MBIP and NKX2-1 genes, with the deletions identified in our family and in previously published cases. Present paper
